


1 **Supplemental Appendix**

2 **SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with**
3 **antigenically similar SARS-CoV-2 variants**

4
5 John Kubale^{1#}, Charles Gleason^{2,6#}, Juan Manuel Carreño^{2,6}, Komal Srivastava^{2,6}, Gagandeep
6 Singh^{2,6}, PARIS Study Team^{2,6}, Aubree Gordon^{1*}, Florian Krammer^{2,5,6*}, Viviana Simon^{2,3,4,5,6*}

7
8 **Supplemental Figure S1**



9
10

11 **Supplemental Figure S1: Duration of study follow-up prior for unvaccinated PARIS**
12 **participants included in the protection dataset**

13 (A) The time between first and final pre-vaccine antibody measurements for each participant is
14 shown graphically. The total length of follow-up for unvaccinated participants varies substantially
15 since the SARS-CoV-2 vaccine rollout for health care workers started in the middle of December
16 2020.

17 (B) Enrollment in the PARIS cohort and follow up are shown. PARIS began in April 2020 and
18 continued recruitment throughout the year. The graph summarizes all the pre-vaccination visits
19 for each participant. The number of unvaccinated participants in PARIS declined sharply when
20 SARS-CoV-2 vaccinations became available in December 2020 limiting the number of follow up
21 visits included in the study. Vaccination became mandatory for Mount Sinai staff members in
22 September 2021.